.jpeg?bc=ffffff&h=430&w=280&rev=f6cee49c89914fb79eb9bb4962695542&hash=D0940BA1C763A9B45F39413981B8904F)
- Y818
- +852 3400 8795
- zhiwu.tan@polyu.edu.hk
ORCID ID
SCOPUS IDResearch Overview
Our research focuses on understanding the molecular and cellular mechanisms by which T cells provide protective and therapeutic immunity against cancers, with the goal of developing novel immunotherapies based on these mechanistic basis.
Research Interests
Education and Academic Qualifications
- Bachelor of Science in Pharmaceutical Science, Peking University
- Master of Science in Medicinal Chemistry, Peking University
- Doctor of Philosophy, Faculty of Medicine, The University of Hong Kong
Academic and Professional Experience
- Member, The European Association for Cancer Research
- Member, The American Association of Immunologists
Achievements
- Immuno-Oncolytic Modified Vaccinia Tian Tan Virus and Methods of Treating Cancer. US20210085736A1
- PD1-Based Vaccination Composition and Methods Thereof. WO/2021/164563
- Tan, Z.; Chiu, M. S.; Yue, M.; Kwok, H. Y.; Tse, M. H.; Wen, Y.; Chen, B.; Yang, D.; Zhou, D.; Song, Y. Q.; Man, K.; Chen, Z. Enhancing the efficacy of vaccinia-based oncolytic virotherapy by inhibiting CXCR2-mediated MDSC trafficking. J Leukoc Biol 2024, 115, 633–646. DOI: 10.1093/jleuko/qiad150
- Chen, S.; Tan, Z.; Liao, P.; Li, Y.; Qu, Y.; Zhang, Q.; Yang, M.; Chan, K. W. Y.; Zhang, L.; Man, K.; Chen, Z.; Sun, D. Biodegradable Microrobots for DNA Vaccine Delivery. Advanced Healthcare Materials 2023, 12, 2202921. DOI: https://doi.org/10.1002/adhm.202202921
- Tan, Z.; Chiu, M. S.; Yang, X.; Yue, M.; Cheung, T. T.; Zhou, D.; Wang, Y.; Chan, A. W.; Yan, C. W.; Kwan, K. Y.; Wong, Y. C.; Li, X.; Zhou, J.; To, K. F.; Zhu, J.; Lo, C. M.; Cheng, A. S.; Chan, S. L.; Liu, L.; Song, Y. Q.; Man, K.; Chen, Z. Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients. Gut 2023, 72, 1568–1580. DOI: 10.1136/gutjnl-2022-327133
- Tan, Z.; Chiu, M. S.; Yan, C. W.; Man, K.; Chen, Z. Eliminating mesothelioma by AAV-vectored, PD1-based vaccination in the tumor microenvironment. Mol Ther Oncolytics 2021, 20, 373–386. DOI: 10.1016/j.omto.2021.01.010
- Tan, Z.; Chiu, M. S.; Yan, C. W.; Wong, Y. C.; Huang, H.; Man, K.; Chen, Z. Antimesothelioma Immunotherapy by CTLA-4 Blockade Depends on Active PD1-Based TWIST1 Vaccination. Mol Ther Oncolytics 2020, 16, 302–317. DOI: 10.1016/j.omto.2020.01.009
- Tan, Z.; Liu, L.; Chiu, M. S.; Cheung, K. W.; Yan, C. W.; Yu, Z.; Lee, B. K.; Liu, W.; Man, K.; Chen, Z. Virotherapy-recruited PMN-MDSC infiltration of mesothelioma blocks antitumor CTL by IL-10-mediated dendritic cell suppression. Oncoimmunology 2019, 8, e1518672. DOI: 10.1080/2162402x.2018.1518672
- Tan, Z.; Zhou, J.; Cheung, A. K.; Yu, Z.; Cheung, K. W.; Liang, J.; Wang, H.; Lee, B. K.; Man, K.; Liu, L.; Yuen, K. Y.; Chen, Z. Vaccine-elicited CD8+ T cells cure mesothelioma by overcoming tumor-induced immunosuppressive environment. Cancer Res 2014, 74, 6010–6021. DOI: 10.1158/0008-5472.Can-14-0473
- Zhou, J.; Cheung, A. K.; Liu, H.; Tan, Z.; Tang, X.; Kang, Y.; Du, Y.; Wang, H.; Liu, L.; Chen, Z. Potentiating functional antigen-specific CD8⁺ T cell immunity by a novel PD1 isoform-based fusion DNA vaccine. Mol Ther 2013, 21, 1445–1455. DOI: 10.1038/mt.2013.63
- Zhou, J.; Cheung, A. K.; Tan, Z.; Wang, H.; Yu, W.; Du, Y.; Kang, Y.; Lu, X.; Liu, L.; Yuen, K. Y.; Chen, Z. PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in mice. J Clin Invest 2013, 123, 2629–2642. DOI: 10.1172/jci64704
- Tan, Z.; Li, J.; Pang, R.; He, S.; He, M.; Tang, S.; Hewlett, I.; Yang, M. Screening and evaluation of thiourea derivatives for their HIV capsid and human cyclophilin A inhibitory activity. Medicinal Chemistry Research 2011, 20, 314–320. DOI: 10.1007/s00044-010-9315-4
